If we get involved, are we encouraging risky behavior or practicing harm reduction
Tretinoin, niacinamide, estriol, and GHK-Cu all have extensive safety data for long-term topical application
Oxamate, but not selective targeting of LDH-A, inhibits medulloblastoma cell glycolysis, growth and motility
Results of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial, which compared dapagliflozin (10 mg once daily) to placebo, found that dapagliflozin was associated with a 44% reduction in a composite of adverse kidney outcomes and a 29% reduction in death from cardiovascular causes or hospitalization for heart failure
Notably, tirzepatide is a dual incretin receptor agonist that activates both the glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor, distinguishing it from other GLP-1-specific agonists
These are protective layers that bacteria build around themselves that make them much harder to get rid of